Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 851311 / ISIN: CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

07.06.24		Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (Roche Holding AG)
07.06.24		Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (GlobeNewswire)
29.05.24		FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
29.05.24		FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
27.05.24		Changes to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
27.05.24		Wechsel in der erweiterten Konzernleitung von Roche (GlobeNewswire)
27.05.24		Changes to the Roche Enlarged Corporate Executive Committee (GlobeNewswire)
22.05.24		Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk (Roche Holding AG)
22.05.24		Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk (GlobeNewswire)
21.05.24		FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
21.05.24		FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
16.05.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity (Roche Holding AG)
16.05.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity (GlobeNewswire)
15.05.24		Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer (GlobeNewswire)
15.05.24		Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer (Roche Holding AG)
24.04.24		[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produ (GlobeNewswire)
24.04.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 (GlobeNewswire)
19.04.24		FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer (GlobeNewswire)
17.04.24		Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS (GlobeNewswire)
15.04.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study (GlobeNewswire)
11.04.24		Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis (GlobeNewswire)
26.03.24		Roche receives FDA approval for the first molecular test to screen for malaria in blood donors (GlobeNewswire)
12.03.24		Roche Annual General Meeting 2024 (GlobeNewswire)
12.03.24		Roche Generalversammlung 2024 (GlobeNewswire)
05.03.24		Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when add (GlobeNewswire)
25.02.24		New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies (GlobeNewswire)
16.02.24		FDA approves Xolair as first and only medicine for children and adults with one or more food allergies (GlobeNewswire)
01.02.24		New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO) (GlobeNewswire)
01.02.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline (GlobeNewswire)
01.02.24		[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER) (GlobeNewswire)
16.01.24		European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types (GlobeNewswire)
29.12.23		Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform (GlobeNewswire)
19.12.23		FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results (GlobeNewswire)
15.12.23		Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices (GlobeNewswire)
11.12.23		New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma (GlobeNewswire)
09.12.23		New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A (GlobeNewswire)
08.12.23		Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treat (GlobeNewswire)
08.12.23		Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
05.12.23		Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
04.12.23		Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes (GlobeNewswire)
27.11.23		Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection (GlobeNewswire)
16.11.23		Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List (GlobeNewswire)
14.11.23		Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types (GlobeNewswire)
09.11.23		Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation (GlobeNewswire)
30.10.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functio (GlobeNewswire)
27.10.23		[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) (GlobeNewswire)
23.10.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory (GlobeNewswire)
19.10.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products (GlobeNewswire)
19.10.23		[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum trotz Rückgang der Nachfrage nach COVID-19-Produkten (GlobeNewswire)
18.10.23		Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns (GlobeNewswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Roche Peer Group Nachrichten

29.04.25		AstraZeneca-Aktie dennoch niedriger: Wachstumskurs zum Jahresstart
29.04.25		Dow Jones 30 Industrial-Titel Merck-Aktie: So viel Gewinn hätte ein Investment in Merck von vor 5 Jahren eingebracht
29.04.25		S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte eine Pfizer-Investition von vor 5 Jahren eingebracht
29.04.25		Merck-Analyse: DZ BANK bewertet Merck-Aktie mit Kaufen in neuer Analyse
29.04.25		Ausblick: Pfizer legt Quartalsergebnis vor
29.04.25		Novartis-Aktie im Plus: Prognose nach starkem Start ins Jahr erhöht
29.04.25		DAX 40-Wert Fresenius SE-Aktie: So viel Gewinn hätte ein Investment in Fresenius SE von vor 3 Jahren eingebracht
29.04.25		EURO STOXX 50-Wert Sanofi-Aktie: So viel Gewinn hätte ein Sanofi-Investment von vor einem Jahr eingefahren

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	30.04.2025 07:32
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie

WKN: 851311 / ISIN: CH0012032113

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten